16 February 2024 Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis read more
4 January 2024 Kyverna’s KYV-101 Receives U.S. FDA Clearance for Treatment of Patients With Refractory, Progressive Multiple Sclerosis in the KYSA-7 Phase 2 Trial read more
3 January 2024 Alterome Named BioSpace’s NextGen Class of 2024: Top Life Sciences Startups to Watch This Year read more
